Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

被引：97

作者：

Aalders, Kim C. ^{[1
]}

Tryfonidis, Konstantinos ^{[1
]}

Senkus, Elbieta ^{[2
]}

Cardoso, Fatima ^{[3
]}

机构：

[1] European Org Res Treatment Canc, Dept Med, Brussels, Belgium

[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland

[3] Champalimaud Canc Ctr, Breast Unit, Lisbon, Portugal

来源：

CANCER TREATMENT REVIEWS | 2017年 / 53卷

关键词：

Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab; ENDOTHELIAL GROWTH-FACTOR; PHASE-III TRIAL; TYROSINE KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BEVACIZUMAB PLUS PACLITAXEL; OPEN-LABEL; 1ST-LINE TREATMENT; NEOADJUVANT CHEMOTHERAPY; TUMOR-CELLS; FACTOR VEGF;

D O I：

10.1016/j.ctrv.2016.12.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：98 / 110

页数：13

共 50 条

[21] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, Naveen S.
Reynolds, Andrew R.
ANGIOGENESIS, 2014, 17 (03) : 471 - 494
[22] Anti-angiogenic strategies in breast cancer: An update
Gropper A.B.
Mayer E.L.
Current Breast Cancer Reports, 2010, 2 (4) : 174 - 181
[23] VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Sharma, P. S.
Sharma, R.
Tyagi, T.
CURRENT CANCER DRUG TARGETS, 2011, 11 (05) : 624 - 653
[24] Current status and future of anti-angiogenic drugs in lung cancer
Yan, Xuan
Zhao, Zhangyan
Tang, Haicheng
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2009 - 2023
[25] Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Teleanu, Raluca Ioana
Chircov, Cristina
Grumezescu, Alexandru Mihai
Teleanu, Daniel Mihai
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
[26] Present and future perspectives of anti-angiogenic therapy
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (SUPPL 3) : S81 - S83
[27] New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update
Ghasemali, Samaneh
Farajnia, Safar
Barzegar, Abolfazl
Rahmati-Yamchi, Mohammad
Baghban, Roghayyeh
Rahbarnia, Leila
Nodeh, Hamid R. Y.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2021, 21 (01) : 3 - 19
[28] Angiogenesis and anti-angiogenic therapy in prostate cancer
Mukherji, Deborah
Temraz, Sally
Wehbe, David
Shamseddine, Ali
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) : 122 - 131
[29] Anti-angiogenic therapies for metastatic colorectal cancer:Current and future perspectives
Inês Marques
António Araújo
Ramon Andrade de Mello
World Journal of Gastroenterology, 2013, 19 (44) : 7955 - 7971
[30] Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Yolla
Kreidieh, Malek
El Hajj, Hiba
Khalifeh, Ibrahim
Mukherji, Deborah
Temraz, Sally
Shamseddine, Ali
FRONTIERS IN ONCOLOGY, 2020, 10

← 1 2 3 4 5 →